SE0400850D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE0400850D0
SE0400850D0 SE0400850A SE0400850A SE0400850D0 SE 0400850 D0 SE0400850 D0 SE 0400850D0 SE 0400850 A SE0400850 A SE 0400850A SE 0400850 A SE0400850 A SE 0400850A SE 0400850 D0 SE0400850 D0 SE 0400850D0
Authority
SE
Sweden
Prior art keywords
novel compounds
compounds
metalloproteinase
mmp
inhibitors
Prior art date
Application number
SE0400850A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Eriksson
Matti Lepistoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0400850A priority Critical patent/SE0400850D0/xx
Publication of SE0400850D0 publication Critical patent/SE0400850D0/xx
Priority to PCT/SE2005/000448 priority patent/WO2005095362A1/en
Priority to JP2007506108A priority patent/JP2007530672A/ja
Priority to EP05722275A priority patent/EP1732903B1/en
Priority to AT05722275T priority patent/ATE423105T1/de
Priority to ES05722275T priority patent/ES2320679T3/es
Priority to US10/593,543 priority patent/US20070219217A1/en
Priority to CNA2005800176722A priority patent/CN1960979A/zh
Priority to DE602005012811T priority patent/DE602005012811D1/de
Priority to HK07105624.6A priority patent/HK1099751A1/xx
Priority to US12/538,522 priority patent/US20090299066A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0400850A 2004-03-30 2004-03-30 Novel Compounds SE0400850D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE0400850A SE0400850D0 (sv) 2004-03-30 2004-03-30 Novel Compounds
DE602005012811T DE602005012811D1 (de) 2004-03-30 2005-03-29 Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
AT05722275T ATE423105T1 (de) 2004-03-30 2005-03-29 Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
JP2007506108A JP2007530672A (ja) 2004-03-30 2005-03-29 喘息およびｃｏｐｄの処置のためのｍｍｐ阻害剤としてのトリアゾロン誘導体
EP05722275A EP1732903B1 (en) 2004-03-30 2005-03-29 Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd
PCT/SE2005/000448 WO2005095362A1 (en) 2004-03-30 2005-03-29 Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd
ES05722275T ES2320679T3 (es) 2004-03-30 2005-03-29 Derivados de triazolona como inhibidores de mmp para el tratamiento del asma y epoc.
US10/593,543 US20070219217A1 (en) 2004-03-30 2005-03-29 Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd
CNA2005800176722A CN1960979A (zh) 2004-03-30 2005-03-29 作为mmp抑制剂用于治疗哮喘和慢性阻塞性肺病的三唑酮衍生物
HK07105624.6A HK1099751A1 (en) 2004-03-30 2007-05-29 Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd
US12/538,522 US20090299066A1 (en) 2004-03-30 2009-08-10 Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400850A SE0400850D0 (sv) 2004-03-30 2004-03-30 Novel Compounds

Publications (1)

Publication Number Publication Date
SE0400850D0 true SE0400850D0 (sv) 2004-03-31

Family

ID=32105805

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0400850A SE0400850D0 (sv) 2004-03-30 2004-03-30 Novel Compounds

Country Status (10)

Country Link
US (2) US20070219217A1 (es)
EP (1) EP1732903B1 (es)
JP (1) JP2007530672A (es)
CN (1) CN1960979A (es)
AT (1) ATE423105T1 (es)
DE (1) DE602005012811D1 (es)
ES (1) ES2320679T3 (es)
HK (1) HK1099751A1 (es)
SE (1) SE0400850D0 (es)
WO (1) WO2005095362A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
BRPI0614063A2 (pt) 2005-07-26 2011-03-09 Sanofi Aventis derivados de cicloexilamina isoquinolona
AU2006274245B2 (en) 2005-07-26 2011-11-24 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
NZ577981A (en) 2006-12-27 2011-12-22 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
JP5318779B2 (ja) 2006-12-27 2013-10-16 サノフイ シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
MX337862B (es) 2008-04-28 2016-03-16 Revalesio Corp Composiciones y métodos para el tratamiento de la esclerosis multiple.
ES2541827T3 (es) 2008-06-24 2015-07-27 Sanofi Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa
US8524737B2 (en) 2008-06-24 2013-09-03 Sanofi Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
KR101607090B1 (ko) 2008-06-24 2016-03-29 사노피 6-치환된 이소퀴놀린 및 이소퀴놀리논
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
KR20120133386A (ko) * 2010-02-22 2012-12-10 글락소스미스클라인 엘엘씨 지방산 신타제 억제제로서의 트리아졸론
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
CN104876917B (zh) * 2015-06-16 2017-09-19 上海皓元医药股份有限公司 用作脂肪酸合成酶抑制剂的三唑酮的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19504627A1 (de) * 1995-02-13 1996-08-14 Bayer Ag Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
AU766191B2 (en) * 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
AU1196601A (en) * 1999-10-12 2001-04-23 Board Of Trustees Of The Leland Stanford Junior University Methods of diagnosing and treating urinary incontinence
EP1110958A1 (en) * 1999-12-20 2001-06-27 Ucb, S.A. Alpha-arylethylpiperazine derivatives as neurokinin antagonists
IL151018A0 (en) * 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
GB0203412D0 (en) * 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
AU2003220215B2 (en) * 2002-03-13 2007-01-04 Schering Corporation NK1 antagonists
AR039625A1 (es) * 2002-04-18 2005-03-02 Merck & Co Inc Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
US20040010010A1 (en) * 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
WO2003101964A1 (fr) * 2002-05-31 2003-12-11 Takeda Pharmaceutical Company Limited Derive piperidine, procede de production, et utilisation
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
KR20060106106A (ko) * 2005-04-06 2006-10-12 삼성전자주식회사 고속 레벨 쉬프터

Also Published As

Publication number Publication date
HK1099751A1 (en) 2007-08-24
WO2005095362A1 (en) 2005-10-13
JP2007530672A (ja) 2007-11-01
EP1732903A1 (en) 2006-12-20
CN1960979A (zh) 2007-05-09
ATE423105T1 (de) 2009-03-15
US20070219217A1 (en) 2007-09-20
ES2320679T3 (es) 2009-05-27
DE602005012811D1 (de) 2009-04-02
EP1732903B1 (en) 2009-02-18
US20090299066A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
DE602005012811D1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
SE0202133D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
TW200635917A (en) Novel compounds
SE0401762D0 (sv) Novel compounds
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
SE0200920D0 (sv) Novel compounds
TW200801003A (en) Novel compounds
SE0202539D0 (sv) Compounds
SE0104140D0 (sv) Novel Compounds
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
ATE433447T1 (de) Pyrimiidinverbindungen
UA93425C2 (ru) Производные гидантоина, которые применяются kak mmp ингибиторы
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
NO20081217L (no) Nye benzotiazolonderivater
TW200745084A (en) Novel compounds
TW200833670A (en) Novel compounds 569
TW200605888A (en) Novel compounds
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
NO20062900L (no) Nye forbindelser
SE0303541D0 (sv) New compounds
TW200740781A (en) Novel compounds
ATE449069T1 (de) Aminopropanolderivate